株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界における糖尿病性腎症市場

Global Diabetic Nephropathy Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 298333
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
世界における糖尿病性腎症市場 Global Diabetic Nephropathy Market 2014-2018
出版日: 2014年03月14日 ページ情報: 英文 64 Pages
概要

糖尿病性腎症(DN)の世界市場は、2013年から2018年にかけて、5.19%のCAGRで拡大する見込みです。

当レポートでは、世界の糖尿病性腎症市場の現状と将来の見通し、主要企業の分析などを提供しており、概略以下の構成でお届けします。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品
  • 製品プロファイル

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • 米国のDN市場
  • 欧州のDN市場
  • ファイブフォース分析

第7章 パイプラインの概要

第8章 罹患率と有病率

第9章 地理区分

  • 南北アメリカのDN市場
  • EMEA(欧州・中東・アフリカ)地域のDN市場
  • アジア太平洋地域のDN市場

第10章 購入基準

第11章 市場成長因子

第12章 成長因子とその影響

第13章 市場の課題

第14章 成長因子と課題の影響

第15章 市場動向

第16章 動向とその影響

第17章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
  • その他の有力ベンダー

第18章 主要ベンダーの分析

  • Merck & Co. Inc.
  • 三菱田辺製薬
  • Novartis AG
  • Sanofi S.A.

第19章 関連レポート

目次
Product Code: IRTNTR3393

About Diabetic Nephropathy

Diabetic nephropathy is a disease of the kidney glomerulus, which is caused by high blood sugar. When diabetes damages kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the blood, this results in diabetic nephropathy, which is also known as diabetic kidney disease. Severe damage can lead to kidney failure or irreversible ESRD, requiring dialysis or a kidney transplant. Hypertension, or high blood pressure, is a complication of diabetes that is believed to contribute most directly to diabetic nephropathy. Treatment to limit progression of diabetic nephropathy involves glycemic control and blood pressure control.

TechNavio's analysts forecast the Global Diabetic Nephropathy market will grow at a CAGR of 5.19 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Diabetic Nephropathy market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various diabetic nephropathy drugs available in the market.

TechNavio's report, the Global Diabetic Nephropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Nephropathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Novartis AG
  • Sanofi S.A.

Other Prominent Vendors

  • AbbVie Inc.
  • Ampio Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • ChemoCentryx Inc.
  • Eli Lilly and Co.
  • GenKyoTex S.A.
  • Glycadia Pharmaceuticals Inc.
  • IMMD Inc.
  • Mesoblast Ltd.
  • NephroGenex Inc.
  • Novo Nordisk A/S
  • NOXXON Pharma AG
  • OncoImmune Inc.
  • Pfizer Inc.
  • PhytoHealth Corp.
  • Questcor Pharmaceuticals Inc.
  • Reata Pharmaceuticals Inc.

Key Market Driver

  • Increase in Prevalence of Diabetes.

For a full, detailed list, view our report.

Key Market Challenge

  • Increasing Number of Patent Expirations.

For a full, detailed list, view our report.

Key Market Trend

  • Increase in Awareness of Diabetic Nephropathy Drugs.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. DN Market in the US
    • 06.3.1. Market Size and Forecast
  • 06.4. DN Market in Europe
    • 06.4.1. Market Size and Forecast
  • 06.5. Five Forces Analysis

07. Pipeline Snapshot

08. Rate of Incidence and Prevalence

09. Geographical Segmentation

  • 09.1. DN Market in the Americas
    • 09.1.1. Market Size and Forecast
  • 09.2. DN Market in the EMEA Region
    • 09.2.1. Market Size and Forecast
  • 09.3. DN Market in the APAC Region
    • 09.3.1. Market Size and Forecast

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2013
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. Merck & Co. Inc.
    • 18.1.1. Business Overview
    • 18.1.2. Business Segmentation
    • 18.1.3. Key Information
    • 18.1.4. SWOT Analysis
  • 18.2. Mitsubishi Tanabe Pharma Corp.
    • 18.2.1. Business Overview
    • 18.2.2. Key Information
    • 18.2.3. SWOT Analysis
  • 18.3. Novartis AG
    • 18.3.1. Business Overview
    • 18.3.2. Business Segmentation
    • 18.3.3. Key Information
    • 18.3.4. SWOT Analysis
  • 18.4. Sanofi S.A.
    • 18.4.1. Business Overview
    • 18.4.2. Business Segmentation
    • 18.4.3. Key Information
    • 18.4.4. SWOT Analysis

19. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global DN Market 2013-2018 (US$ billion)
  • Exhibit 3: DN Market in the US 2013-2018 (US$ billion)
  • Exhibit 4: DN Market in Europe 2013-2018 (US$ billion)
  • Exhibit 5: Global DN Market by Geographical Segmentation 2013
  • Exhibit 6: DN Market in the Americas 2013-2018 (US$ billion)
  • Exhibit 7: DN Market in the EMEA Region 2013-2018 (US$ billion)
  • Exhibit 8: DN Market in the APAC Region (US$ billion)
  • Exhibit 9: Global DN Market by Geographical Segmentation
  • Exhibit 10: Business Segmentation of Merck & Co. Inc.
  • Exhibit 11: Business Segmentation of Novartis AG
  • Exhibit 12: Business Segmentation of Sanofi S.A.
Back to Top